cryopreservation
PreclinicalBiologic
cryopreservation is one of 44 biologic programs targeting Graft Versus Host Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
103 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Amevive
AstellasPhase 3
Zinbryta
RochePhase 3
Cellcept
NovartisPhase 3
Cellcept
RochePhase 2
Pulmicort
SSalix
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Itacitinib
IncytePhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Graft Versus Host Disease1 trial
Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment
Unknown status·—·N/A·NCT03361254·5 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cryopreservation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- CCentral Hospital, Nancy, France